(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 April 2017 (20.04.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/066554 A1

(51) International Patent Classification:
*A61K 9/00* (2006.01) *A61K 9/19* (2006.01)
*A61K 9/14* (2006.01)

(21) International Application Number:
PCT/US2016/057019

(22) International Filing Date:
14 October 2016 (14.10.2016)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/242,412 16 October 2015 (16.10.2015) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **CHEN, Hunter**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **SCHLESINGER, Erica**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: **ZAHNER, Joseph**; Kutak Rock LLP, 2300 Main Street, Suite 800, Kansas City, Missouri 64108 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

*[Continued on next page]*

(54) Title: STABLE PROTEIN COMPOSITIONS





FIGURE 9

(57) Abstract: Stable pharmaceutical formulations and drug delivery devices are disclosed. In certain embodiments, the drug delivery device contains a reservoir when implanted into a patient is in partial contact with the tissue environment. The reservoir remains in contact with the environment via a porous structure in the housing of the delivery device. The reservoir contains a combination of the therapeutic biomolecule and a second molecule that serves to stabilize and restrict the solubility of the therapeutic biomolecule, thereby controlling the amount of therapeutic biomolecule that is in solution. The concentration of the soluble therapeutic biomolecule or the size of the surface area of the porous structure controls the rate of delivery of the therapeutic biomolecule to the target tissue.

WO 2017/066554 A1

**Declarations under Rule 4.17**:

— *of inventorship (Rule 4.17(iv))*

**Published**:

— *with international search report (Art. 21(3))*